1-2 of 2
Ron Gilissen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy P.S. Perera, Eleonora Jovcheva, Laurence Mevellec, Jorge Vialard, Desiree De Lange, Tinne Verhulst, Caroline Paulussen, Kelly Van De Ven, Peter King, Eddy Freyne, David C. Rees, Matthew Squires, Gordon Saxty, Martin Page, Christopher W. Murray, Ron Gilissen, George Ward, Neil T. Thompson, David R. Newell, Na Cheng, Liang Xie, Jennifer Yang, Suso J. Platero, Jayaprakash D. Karkera, Christopher Moy, Patrick Angibaud, Sylvie Laquerre, Matthew V. Lorenzi
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (6): 1010–1020.
https://doi.org/10.1158/1535-7163.MCT-16-0589
Published: 01 June 2017
View article titled, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Open the PDF for Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor in another window
Includes: Supplementary data
Journal Articles

JNJ-26481585, a novel “second-generation” oral pan-histone deacetylase (HDAC) inhibitor, shows broad-spectrum preclinical antitumoral activity against solid and hematological malignancies

Janine Arts, Ann Marien, Peter King, Wim Floren, Ann Belien, Lut Janssen, Isabelle Pilatte, Bruno Roux, Laurence Decrane, Ron Gilissen, Luc Andries, Manfred Jung, Marc Jardin, Michel Janicot, Kristof Emelen, Patrick Angibaud
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A264.
Published: 01 November 2007
View article titled, JNJ-26481585, a novel “second-generation” oral pan-histone deacetylase (HDAC) inhibitor, shows broad-spectrum preclinical antitumoral activity against solid and hematological malignancies